Garcia Gonzalez M.M.,Servei de Pediatria |
Calvo M.,Servei de Pediatria |
Villalobos P.,Servei de Pediatria |
Schneider S.,Servei de Pediatria |
And 4 more authors.
Pediatria Catalana | Year: 2010
Introduction. Congenital ichthyosis, which presents as collodion baby, is a very rare disorder. In our national collaborative study of congenital malformations (ECEMC) only one out of more than 100.000 newborns is diagnosed as having congenital ichthyosis. Case report. We describe the case of a trasient collodion baby who, despite the prominent clinical findings at birth, had a bening course. Comments. The differential diagnosis of possible clinical disorders that can manifest as collodion baby in the perinatal period is discussed. Molecular genetic studies are also reviewed.
Effect of imiquimod as compared with surgery on the cancerization field in basal cell carcinoma [Efecto del imiquimod comparado con la cirugía sobre el campo de cancerización en el carcinoma basocelular]
Graells J.,Servei de Dermatologia |
Ojeda R.M.,Servei de Dermatologia |
Garcia-Cruz A.,Servei de Dermatologia
Actas Dermo-Sifiliograficas | Year: 2014
Background Patients with basal cell carcinoma (BCC) have an increased risk of subsequent BCCs. It is possible that imiquimod might reduce this risk by acting on the cancerization field. Objective To examine the ability of imiquimod to reduce subsequent BCCs. Methods Retrospective cohort study of patients with BCC treated at our hospital between 2003 and 2011. The patients were divided into 2 groups depending on whether they had been treated with surgery or with imiquimod. Comparing the 2 groups, we analyzed the development of new BCCs, the time that elapsed between first and subsequent tumors, and the site of occurrence of the second BCC with respect to the first one (local, same lymphatic drainage basin or anatomic region, or other). Survival methods were used to analyze the data. Results We reviewed the charts of 623 patients. Of these, 550 had been treated with surgery (88.3%) and 71 with imiquimod (11.4%). Overall, a second BCC occurred in 36.4% of patients (n = 227). The rate of occurrence was 38.2% in the surgery group and 23.9% in the imiquimod group (P =.02). The hazard ratio for the occurrence of a subsequent BCC was 2.13 (95% CI, 1.28-3.53) for patients treated with surgery compared with those treated with imiquimod. Imiquimod reduced the risk of a second BCC locally, regionally, and in the lymphatic drainage area. Our findings are limited by the retrospective nature of our study and the small number of patients treated with imiquimod. Conclusions Imiquimod may reduce the risk of subsequent BCC in patients treated for BCC and its effect could last for up to 2 years in local, regional and lymphatic cancerization fields. We believe that the cancerization field concept should be expanded to include not only the local area, but also the pertinent anatomic region and the regional lymphatic drainage area. © 2012 Elsevier España, S.L. and AEDV. All rights reserved.